AbbVie Inc. (ABBV) Operating Cash Flow CAGR:N/A(TTM)
The operating cash flow cagr for AbbVie Inc. (ABBV) is N/A over the latest trailing 12-month period. Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
The operating cash flow cagr for AbbVie Inc. (ABBV) stock is N/A over the past 12 months. The 3 year average growth rate is -4.32% and the 5 year cagr is 2.62%. Operating cash flow CAGR measures the compound annual growth rate of the cash AbbVie Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history. The 1-year (TTM) figure is omitted: a one-year rate off a single quarter's base is volatile; the multi-year figures are the reliable read.
ABBV Operating Cash Flow CAGR Chart
AbbVie Inc. (ABBV)
ABBV Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $18.81B | $19.03B | +$224.00M | +1.19% | +1.19% |
| 2024 | $22.84B | $18.81B | $-4.03B | -17.66% | -17.66% |
| 2023 | $24.94B | $22.84B | $-2.10B | -8.44% | -8.44% |
| 2022 | $22.78B | $24.94B | +$2.17B | +9.51% | +9.51% |
| 2021 | $17.59B | $22.78B | +$5.19B | +29.50% | +29.50% |
| 2020 | $13.32B | $17.59B | +$4.26B | +32.00% | +32.00% |
| 2019 | $13.43B | $13.32B | $-103.00M | -0.77% | -0.77% |
| 2018 | $9.96B | $13.43B | +$3.47B | +34.81% | +34.81% |
| 2017 | $7.04B | $9.96B | +$2.92B | +41.46% | +41.46% |
| 2016 | $7.54B | $7.04B | $-494.00M | -6.56% | -6.56% |
| 2015 | $3.55B | $7.54B | +$3.99B | +112.31% | +112.31% |
| 2014 | $6.27B | $3.55B | $-2.72B | -43.37% | -43.37% |
| 2013 | $6.34B | $6.27B | $-78.00M | -1.23% | -1.23% |
| 2012 | $6.25B | $6.34B | +$98.04M | +1.57% | +1.57% |
| 2011 | $4.98B | $6.25B | +$1.27B | +25.54% | +25.54% |
| 2010 | $5.37B | $4.98B | $-391.34M | -7.29% | -7.29% |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael